Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
-
Full year 2024 revenue of
, up$6.4 billion 2% as-reported and3% at constant currency -
Full year 2024 diluted earnings per share of
and non-GAAP Adjusted diluted earnings per share of$3.33 $4.11 -
Full year 2024 Adjusted EBITDA of
inclusive of$1.96 billion of IPR&D, representing a$81 million 30.6% Adjusted EBITDA margin -
Full year 2025 financial guidance ranges provided
-
Full year revenue range of
-$6.12 5 billion , inclusive of an approximate$6.32 5 billion year-over-year negative impact from foreign exchange$200 million -
Adjusted EBITDA margin range of
31.0% -32.0%
-
Full year revenue range of
“In 2024 we achieved our third year of constant currency revenue growth and delivered Adjusted EBITDA margin expansion ex-IPR&D,” said Kevin Ali, Organon's chief executive officer. “Our 2025 financial guidance reflects the potential for a fourth year of constant currency revenue growth despite the loss of exclusivity (LOE) of our second largest product, Atozet, in certain markets. Further, we will continue to be extremely disciplined on operating costs to support Adjusted EBITDA margins ex-IPR&D of
Fourth Quarter 2024 Revenue
in $ millions |
|
Q4 2024 |
|
Q4 2023 |
|
VPY |
|
VPY ex-FX |
||
Women’s Health |
|
$ |
466 |
|
$ |
465 |
|
—% |
|
—% |
Biosimilars |
|
|
163 |
|
|
199 |
|
(18)% |
|
(18)% |
Established Brands |
|
|
935 |
|
|
915 |
|
|
|
|
Other (1) |
|
|
28 |
|
|
19 |
|
|
|
|
Revenue |
|
$ |
1,592 |
|
$ |
1,598 |
|
—% |
|
—% |
Totals may not foot due to rounding and percentages are computed using unrounded amounts. |
||||||||||
(1) Other includes manufacturing sales to third parties. |
For the fourth quarter of 2024, total revenue was
Women’s Health revenue was flat on both an as-reported and ex-FX basis in the fourth quarter of 2024, compared with the fourth quarter of 2023. Nexplanon® (etonogestrel implant) growth of
Biosimilars revenue declined
Established Brands revenue grew
(1) Emgality is a trademark registered in
(2) Vtama was acquired as part of Organon's acquisition of Dermavant Sciences Inc., which closed on October 28, 2024.
Fourth Quarter 2024 Profitability
in $ millions, except per share amounts |
|
Q4 2024 |
|
Q4 2023 |
|
VPY |
||||
Revenues |
|
$ |
1,592 |
|
|
$ |
1,598 |
|
|
—% |
Cost of sales |
|
|
696 |
|
|
|
683 |
|
|
|
Gross profit |
|
|
896 |
|
|
|
915 |
|
|
(2)% |
Non-GAAP Adjusted gross profit (1) |
|
|
965 |
|
|
|
964 |
|
|
—% |
Net income |
|
|
109 |
|
|
|
546 |
|
|
(80)% |
Non-GAAP Adjusted net income (1) |
|
|
235 |
|
|
|
226 |
|
|
|
Diluted Earnings per Share (EPS) |
|
|
0.42 |
|
|
|
2.13 |
|
|
(80)% |
Non-GAAP Adjusted diluted EPS (1) |
|
|
0.90 |
|
|
|
0.88 |
|
|
|
Acquired IPR&D and milestones |
|
|
— |
|
|
|
— |
|
|
— |
Adjusted EBITDA (Non-GAAP) (1,2) |
|
|
448 |
|
|
|
449 |
|
|
—% |
|
|
|
|
|
|
|
||||
|
|
Q4 2024 |
|
Q4 2023 |
|
|
||||
Gross margin |
|
|
56.3 |
% |
|
|
57.3 |
% |
|
|
Non-GAAP Adjusted gross margin (1) |
|
|
60.6 |
% |
|
|
60.3 |
% |
|
|
Adjusted EBITDA margin (Non-GAAP) (1, 2) |
|
|
28.1 |
% |
|
|
28.1 |
% |
|
|
(1) See Tables 4 and 5 for reconciliations of GAAP to non-GAAP financial measures. |
||||||||||
(2) There was no IPR&D or milestone expense impacting Adjusted EBITDA in the fourth quarter comparable periods. |
Gross margin was
Net income for the fourth quarter of 2024 was
Non-GAAP Adjusted EBITDA margin was
Full Year 2024 Revenue
in $ millions |
|
FY 2024 |
|
FY 2023 |
|
VPY |
|
VPY ex-FX |
||
Women’s Health |
|
$ |
1,777 |
|
$ |
1,702 |
|
|
|
|
Biosimilars |
|
|
662 |
|
|
593 |
|
|
|
|
Established Brands |
|
|
3,849 |
|
|
3,847 |
|
—% |
|
|
Other (1) |
|
|
115 |
|
|
121 |
|
(6)% |
|
(6)% |
Revenue |
|
$ |
6,403 |
|
$ |
6,263 |
|
|
|
|
(1) Other includes manufacturing sales to third parties. |
Full year 2024 revenue was
Women’s Health revenue increased
Biosimilars revenue increased
Revenue for Established Brands was flat on an as-reported basis and increased
Full Year 2024 Profitability
in $ millions, except per share amounts |
|
2024 |
|
2023 |
|
VPY |
||||
Revenues |
|
$ |
6,403 |
|
|
$ |
6,263 |
|
|
|
Cost of sales |
|
|
2,688 |
|
|
|
2,515 |
|
|
|
Gross profit |
|
|
3,715 |
|
|
|
3,748 |
|
|
(1)% |
Non-GAAP Adjusted gross profit (1) |
|
|
3,944 |
|
|
|
3,930 |
|
|
—% |
Net income |
|
|
864 |
|
|
|
1,023 |
|
|
(16)% |
Non-GAAP Adjusted net income (1) |
|
|
1,065 |
|
|
|
1,061 |
|
|
—% |
Diluted Earnings per Share (EPS) |
|
|
3.33 |
|
|
|
3.99 |
|
|
(17)% |
Non-GAAP Adjusted diluted EPS (1) |
|
|
4.11 |
|
|
|
4.14 |
|
|
(1)% |
Acquired in-process research & development (IPR&D) and milestones |
|
|
81 |
|
|
|
8 |
|
|
NM |
Adjusted EBITDA (1, 2) |
|
|
1,958 |
|
|
|
1,944 |
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
2024 |
|
|
2023 |
|
|
||
Gross margin |
|
|
58.0 |
% |
|
|
59.8 |
% |
|
|
Non-GAAP Adjusted gross margin (1) |
|
|
61.6 |
% |
|
|
62.7 |
% |
|
|
Adjusted EBITDA margin (1, 2) |
|
|
30.6 |
% |
|
|
31.0 |
% |
|
|
(1) See Tables 4 and 5 for reconciliations of GAAP to non-GAAP financial measures. |
||||||||||
(2) Adjusted EBITDA and Adjusted EBITDA margin include |
Gross margin was
Adjusted EBITDA margin was
Net income for full year 2024 was
Capital Allocation
Today, Organon’s Board of Directors declared a quarterly dividend of
As of December 31, 2024, cash and cash equivalents were
Full Year Guidance
Organon does not provide GAAP financial measures on a forward-looking basis because the company cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts, and acquisition-related expenses. These items are uncertain, depend on various factors, and could be material to Organon’s results computed in accordance with GAAP.
Full year 2024 actual results and 2025 financial guidance are presented below on a non-GAAP basis, except revenue.
|
Full Year 2024 Actuals |
Full Year 2025 Guidance |
Revenue |
|
|
FX translation headwind |
|
|
Adjusted gross margin |
|
|
SG&A |
|
Mid |
R&D |
|
Upper single-digit |
IPR&D* |
|
- |
Adjusted EBITDA margin (Non-GAAP) |
|
|
Interest |
|
|
Depreciation |
|
|
Effective non-GAAP tax rate |
|
|
Fully diluted weighted average shares outstanding |
259M |
~263M |
*The company does not provide guidance for forward-looking IPR&D and milestone expense. |
Webcast Information
Organon will host a conference call at 8:30 a.m. Eastern Time today to discuss its fourth quarter and full year 2024 financial results. To listen to the event and view the presentation slides via webcast, join from the Organon Investor Relations website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website. Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://registrations.events/direct/Q4I5851155
Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.
About Organon
Organon is an independent global healthcare company with a primary mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers over 70 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical partners and innovators looking to commercialize their products by leveraging its scale and agile presence in fast growing international markets.
Organon has geographic scope with significant reach, world-class commercial capabilities, and over 10,000 employees with headquarters located in
For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.
Cautionary Note Regarding Non-GAAP Financial Measures
This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with
In addition, the company’s full-year 2025 guidance measures (other than revenue) are provided on a non-GAAP basis because the company is unable to reasonably predict certain items contained in the GAAP measures. Such items include, but are not limited to, acquisition-related expenses, restructuring and related expenses, stock-based compensation, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts and other items not reflective of the company's ongoing operations.
The company’s management uses the non-GAAP financial measures described above to evaluate the company’s performance and to guide operational and financial decision making. Further, the company’s management believes that these non-GAAP financial measures, which exclude certain items, help to enhance its ability to meaningfully communicate its underlying business performance, financial condition and results of operations.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the
Risks and uncertainties include, but are not limited to, the uncertainty of the clinical trial and regulatory approvals during the expected timeframe, if at all; an inability to adapt to the industry-wide trend toward highly discounted channels; difficulties implementing or executing on Organon’s acquisition strategy, difficulties integrating such acquisitions (including its recent acquisition of Dermavant Sciences Ltd.) or any other failure to recognize the benefits of such acquisitions; changes in tax laws or other tax guidance which could adversely affect our cash tax liability, effective tax rates, and results of operations and lead to greater audit scrutiny; expanded brand and class competition in the markets in which the company operates; global tensions, which may result in disruptions in the broader global economic environment; governmental initiatives that adversely impact our marketing activities, particularly in
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the SEC, including the company’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).
TABLE 1
Organon & Co. |
||||||||||||||
Condensed Consolidated Statement of Income |
||||||||||||||
(Unaudited, $ in millions except shares in thousands and per share amounts) |
||||||||||||||
|
Three Months Ended
|
|
Year Ended
|
|||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||||
Revenues |
$ |
1,592 |
|
$ |
1,598 |
|
|
$ |
6,403 |
|
|
$ |
6,263 |
|
Cost of sales |
|
696 |
|
|
683 |
|
|
|
2,688 |
|
|
|
2,515 |
|
Gross Profit |
|
896 |
|
|
915 |
|
|
|
3,715 |
|
|
|
3,748 |
|
|
|
|
|
|
|
|
|
|||||||
Selling, general and administrative |
|
470 |
|
|
469 |
|
|
|
1,760 |
|
|
|
1,893 |
|
Research and development |
|
130 |
|
|
134 |
|
|
|
469 |
|
|
|
528 |
|
Acquired in-process research and development and milestones |
|
— |
|
|
— |
|
|
|
81 |
|
|
|
8 |
|
Restructuring costs |
|
8 |
|
|
58 |
|
|
|
31 |
|
|
|
62 |
|
Interest expense |
|
132 |
|
|
129 |
|
|
|
520 |
|
|
|
527 |
|
Exchange losses |
|
15 |
|
|
17 |
|
|
|
26 |
|
|
|
42 |
|
Other expense, net |
|
12 |
|
|
4 |
|
|
|
21 |
|
|
|
15 |
|
Income before income taxes |
|
129 |
|
|
104 |
|
|
|
807 |
|
|
|
673 |
|
Income tax expense (benefit) |
|
20 |
|
|
(442 |
) |
|
|
(57 |
) |
|
|
(350 |
) |
Net income |
$ |
109 |
|
$ |
546 |
|
|
$ |
864 |
|
|
$ |
1,023 |
|
|
|
|
|
|
|
|
|
|||||||
Earnings per share: |
|
|
|
|
|
|
|
|||||||
Basic |
$ |
0.42 |
|
$ |
2.14 |
|
|
$ |
3.36 |
|
|
$ |
4.01 |
|
Diluted |
$ |
0.42 |
|
$ |
2.13 |
|
|
$ |
3.33 |
|
|
$ |
3.99 |
|
|
|
|
|
|
|
|
|
|||||||
Weighted average shares outstanding: |
|
|
|
|
|
|
|
|||||||
Basic |
|
257,690 |
|
|
255,617 |
|
|
|
257,046 |
|
|
|
255,239 |
|
Diluted |
|
259,878 |
|
|
256,590 |
|
|
|
259,152 |
|
|
|
256,270 |
|
TABLE 2
Organon & Co. |
||||||||||||||||||||||||||||||||||||
Sales by top products |
||||||||||||||||||||||||||||||||||||
(Unaudited, $ in millions) |
||||||||||||||||||||||||||||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|||||||||||||||||||||||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||||||||||||||||||||||||||
|
|
|
Int’l |
|
Total |
|
|
|
Int’l |
|
Total |
|
|
|
Int’l |
|
Total |
|
|
|
Int’l |
|
Total |
|||||||||||||
Women’s Health |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Nexplanon/Implanon NXT |
$ |
175 |
|
$ |
83 |
|
$ |
258 |
|
$ |
154 |
|
$ |
76 |
|
$ |
231 |
|
$ |
672 |
|
$ |
291 |
|
$ |
963 |
|
$ |
572 |
|
|
$ |
257 |
|
$ |
830 |
Follistim AQ |
|
26 |
|
|
39 |
|
|
65 |
|
|
51 |
|
|
31 |
|
|
83 |
|
|
84 |
|
|
152 |
|
|
237 |
|
|
125 |
|
|
|
136 |
|
|
262 |
NuvaRing (1) |
|
6 |
|
|
18 |
|
|
24 |
|
|
20 |
|
|
19 |
|
|
39 |
|
|
39 |
|
|
75 |
|
|
115 |
|
|
90 |
|
|
|
86 |
|
|
176 |
Ganirelix Acetate Injection |
|
4 |
|
|
24 |
|
|
28 |
|
|
4 |
|
|
18 |
|
|
22 |
|
|
20 |
|
|
89 |
|
|
109 |
|
|
19 |
|
|
|
91 |
|
|
110 |
Marvelon/Mercilon |
|
— |
|
|
31 |
|
|
31 |
|
|
— |
|
|
37 |
|
|
37 |
|
|
— |
|
|
134 |
|
|
134 |
|
|
— |
|
|
|
134 |
|
|
134 |
Jada |
|
18 |
|
|
— |
|
|
18 |
|
|
13 |
|
|
— |
|
|
13 |
|
|
60 |
|
|
1 |
|
|
61 |
|
|
43 |
|
|
|
— |
|
|
43 |
Other Women’s Health (1) (2) |
|
15 |
|
|
27 |
|
|
42 |
|
|
16 |
|
|
26 |
|
|
40 |
|
|
56 |
|
|
104 |
|
|
158 |
|
|
48 |
|
|
|
101 |
|
|
147 |
Biosimilars |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Renflexis |
|
52 |
|
|
13 |
|
|
65 |
|
|
63 |
|
|
14 |
|
|
77 |
|
|
219 |
|
|
55 |
|
|
274 |
|
|
234 |
|
|
|
43 |
|
|
278 |
Ontruzant |
|
6 |
|
|
28 |
|
|
34 |
|
|
10 |
|
|
52 |
|
|
62 |
|
|
29 |
|
|
112 |
|
|
141 |
|
|
46 |
|
|
|
109 |
|
|
155 |
Brenzys |
|
— |
|
|
15 |
|
|
15 |
|
|
— |
|
|
28 |
|
|
28 |
|
|
— |
|
|
77 |
|
|
77 |
|
|
— |
|
|
|
73 |
|
|
73 |
Aybintio |
|
— |
|
|
6 |
|
|
6 |
|
|
— |
|
|
9 |
|
|
9 |
|
|
— |
|
|
28 |
|
|
28 |
|
|
— |
|
|
|
43 |
|
|
43 |
Hadlima |
|
33 |
|
|
11 |
|
|
44 |
|
|
15 |
|
|
8 |
|
|
23 |
|
|
104 |
|
|
38 |
|
|
142 |
|
|
17 |
|
|
|
26 |
|
|
44 |
Established Brands |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Cardiovascular |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Zetia (1) |
|
2 |
|
|
75 |
|
|
77 |
|
|
3 |
|
|
65 |
|
|
67 |
|
|
7 |
|
|
310 |
|
|
317 |
|
|
8 |
|
|
|
314 |
|
|
322 |
Vytorin |
|
2 |
|
|
24 |
|
|
26 |
|
|
1 |
|
|
28 |
|
|
29 |
|
|
6 |
|
|
102 |
|
|
108 |
|
|
6 |
|
|
|
124 |
|
|
129 |
Atozet |
|
— |
|
|
76 |
|
|
76 |
|
|
— |
|
|
122 |
|
|
122 |
|
|
— |
|
|
473 |
|
|
473 |
|
|
— |
|
|
|
519 |
|
|
519 |
Rosuzet |
|
— |
|
|
13 |
|
|
13 |
|
|
— |
|
|
18 |
|
|
18 |
|
|
— |
|
|
49 |
|
|
49 |
|
|
— |
|
|
|
70 |
|
|
70 |
Cozaar/Hyzaar |
|
2 |
|
|
55 |
|
|
57 |
|
|
2 |
|
|
55 |
|
|
57 |
|
|
9 |
|
|
234 |
|
|
243 |
|
|
10 |
|
|
|
272 |
|
|
281 |
Other Cardiovascular (1) (2) |
|
— |
|
|
34 |
|
|
34 |
|
|
— |
|
|
28 |
|
|
29 |
|
|
2 |
|
|
130 |
|
|
133 |
|
|
2 |
|
|
|
136 |
|
|
139 |
Respiratory |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Singulair |
|
2 |
|
|
82 |
|
|
84 |
|
|
2 |
|
|
111 |
|
|
114 |
|
|
9 |
|
|
350 |
|
|
359 |
|
|
11 |
|
|
|
393 |
|
|
404 |
Nasonex (1) |
|
— |
|
|
76 |
|
|
76 |
|
|
— |
|
|
69 |
|
|
69 |
|
|
— |
|
|
276 |
|
|
276 |
|
|
— |
|
|
|
266 |
|
|
266 |
Dulera |
|
42 |
|
|
11 |
|
|
52 |
|
|
40 |
|
|
10 |
|
|
50 |
|
|
162 |
|
|
42 |
|
|
203 |
|
|
156 |
|
|
|
38 |
|
|
194 |
Clarinex |
|
— |
|
|
27 |
|
|
28 |
|
|
1 |
|
|
29 |
|
|
30 |
|
|
3 |
|
|
125 |
|
|
127 |
|
|
5 |
|
|
|
132 |
|
|
136 |
Other Respiratory (1) (2) |
|
13 |
|
|
4 |
|
|
17 |
|
|
8 |
|
|
4 |
|
|
11 |
|
|
38 |
|
|
13 |
|
|
53 |
|
|
49 |
|
|
|
14 |
|
|
64 |
Non-Opioid Pain, Bone and Dermatology |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Arcoxia |
|
— |
|
|
58 |
|
|
58 |
|
|
— |
|
|
51 |
|
|
51 |
|
|
— |
|
|
270 |
|
|
270 |
|
|
— |
|
|
|
257 |
|
|
257 |
Fosamax |
|
— |
|
|
38 |
|
|
38 |
|
|
— |
|
|
35 |
|
|
36 |
|
|
3 |
|
|
147 |
|
|
151 |
|
|
3 |
|
|
|
156 |
|
|
159 |
Diprospan |
|
— |
|
|
36 |
|
|
36 |
|
|
— |
|
|
33 |
|
|
33 |
|
|
— |
|
|
139 |
|
|
139 |
|
|
— |
|
|
|
91 |
|
|
91 |
Vtama |
|
10 |
|
|
1 |
|
|
12 |
|
|
— |
|
|
— |
|
|
— |
|
|
10 |
|
|
1 |
|
|
12 |
|
|
— |
|
|
|
— |
|
|
— |
Other Non-Opioid Pain, Bone and Dermatology (2) |
|
3 |
|
|
69 |
|
|
71 |
|
|
4 |
|
|
64 |
|
|
67 |
|
|
19 |
|
|
279 |
|
|
295 |
|
|
14 |
|
|
|
261 |
|
|
275 |
Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Emgality/Rayvow |
|
— |
|
|
38 |
|
|
38 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
107 |
|
|
107 |
|
|
— |
|
|
|
— |
|
|
— |
Proscar |
|
— |
|
|
22 |
|
|
22 |
|
|
— |
|
|
20 |
|
|
20 |
|
|
1 |
|
|
94 |
|
|
95 |
|
|
1 |
|
|
|
96 |
|
|
97 |
Propecia |
|
1 |
|
|
31 |
|
|
32 |
|
|
2 |
|
|
31 |
|
|
33 |
|
|
6 |
|
|
105 |
|
|
111 |
|
|
7 |
|
|
|
118 |
|
|
125 |
Other (2) |
|
3 |
|
|
83 |
|
|
87 |
|
|
1 |
|
|
78 |
|
|
79 |
|
|
14 |
|
|
314 |
|
|
328 |
|
|
13 |
|
|
|
308 |
|
|
319 |
Other (3) |
|
1 |
|
|
28 |
|
|
28 |
|
|
1 |
|
|
18 |
|
|
19 |
|
|
— |
|
|
115 |
|
|
115 |
|
|
(1 |
) |
|
|
121 |
|
|
121 |
Revenues |
$ |
416 |
|
$ |
1,176 |
|
$ |
1,592 |
|
$ |
411 |
|
$ |
1,187 |
|
$ |
1,598 |
|
$ |
1,572 |
|
$ |
4,831 |
|
$ |
6,403 |
|
$ |
1,478 |
|
|
$ |
4,785 |
|
$ |
6,263 |
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies. |
||||||||||||||||||||||||||||||||||||
(1) Sales of the authorized generic versions of NuvaRing, Zetia and Nasonex were previously included in other and have been reclassified to their respective brand name product. | ||||||||||||||||||||||||||||||||||||
(2) Includes sales of products not listed separately. |
||||||||||||||||||||||||||||||||||||
(3) Other includes manufacturing sales to third parties. |
TABLE 3
Organon & Co. |
|||||||||||
Sales by geographic area |
|||||||||||
(Unaudited, $ in millions) |
|||||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||
|
$ |
420 |
|
$ |
414 |
|
$ |
1,763 |
|
$ |
1,673 |
|
|
416 |
|
|
411 |
|
|
1,572 |
|
|
1,478 |
|
|
244 |
|
|
261 |
|
|
1,050 |
|
|
1,129 |
|
|
213 |
|
|
203 |
|
|
847 |
|
|
864 |
|
|
266 |
|
|
279 |
|
|
1,034 |
|
|
965 |
Other (1) |
|
33 |
|
|
30 |
|
|
137 |
|
|
154 |
Revenues |
$ |
1,592 |
|
$ |
1,598 |
|
$ |
6,403 |
|
$ |
6,263 |
(1) Other includes manufacturing sales to third parties. |
TABLE 4
Organon & Co. |
|||||||||||||||
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics |
|||||||||||||||
(Unaudited, $ in millions) |
|||||||||||||||
|
|||||||||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
GAAP Gross Profit |
$ |
896 |
|
|
$ |
915 |
|
|
$ |
3,715 |
|
|
$ |
3,748 |
|
Adjusted for: |
|
|
|
|
|
|
|
||||||||
Spin-related costs (1) |
|
— |
|
|
|
17 |
|
|
|
6 |
|
|
|
47 |
|
Manufacturing network costs (2) |
|
15 |
|
|
|
— |
|
|
|
54 |
|
|
|
— |
|
Stock-based compensation |
|
4 |
|
|
|
4 |
|
|
|
17 |
|
|
|
17 |
|
Amortization |
|
43 |
|
|
|
28 |
|
|
|
145 |
|
|
|
116 |
|
Acquisition-related costs (3) |
|
7 |
|
|
|
— |
|
|
|
7 |
|
|
|
— |
|
Other |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2 |
|
Adjusted Non-GAAP Gross Profit |
$ |
965 |
|
|
$ |
964 |
|
|
$ |
3,944 |
|
|
$ |
3,930 |
|
|
|
|
|
|
|
|
|
||||||||
(1) Spin-related costs include costs from the separation of Merck & Co., Inc., |
|||||||||||||||
(2) Manufacturing network related costs include costs from exiting manufacturing and supply agreements with Merck & Co., Inc., |
|||||||||||||||
(3) Acquisition-related costs relate to costs from the acquisition of Dermavant. For additional details refer to Table 5. |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
GAAP Gross Margin |
|
56.3 |
% |
|
|
57.3 |
% |
|
|
58.0 |
% |
|
|
59.8 |
% |
Total impact of Non-GAAP adjustments |
|
4.3 |
% |
|
|
3.0 |
% |
|
|
3.6 |
% |
|
|
2.9 |
% |
Adjusted Non-GAAP Gross Margin |
|
60.6 |
% |
|
|
60.3 |
% |
|
|
61.6 |
% |
|
|
62.7 |
% |
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
GAAP Selling, general and administrative expenses |
$ |
470 |
|
|
$ |
469 |
|
|
$ |
1,760 |
|
|
$ |
1,893 |
|
Adjusted for: |
|
|
|
|
|
|
|
||||||||
Spin-related costs (1) |
|
(9 |
) |
|
|
(47 |
) |
|
|
(88 |
) |
|
|
(178 |
) |
Stock-based compensation |
|
(17 |
) |
|
|
(18 |
) |
|
|
(70 |
) |
|
|
(68 |
) |
Acquisition-related costs (2) |
|
(24 |
) |
|
|
— |
|
|
|
(28 |
) |
|
|
— |
|
Other |
|
(3 |
) |
|
|
(3 |
) |
|
|
(3 |
) |
|
|
(91 |
) |
Adjusted Non-GAAP Selling, general and administrative expenses |
$ |
417 |
|
|
$ |
401 |
|
|
$ |
1,571 |
|
|
$ |
1,556 |
|
|
|
|
|
|
|
|
|
||||||||
(1) Spin-related costs include costs from the separation of Merck & Co., Inc., |
|||||||||||||||
(2) Acquisition-related costs relate to costs from the acquisition of Dermavant. For additional details refer to Table 5. |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
GAAP Research and development expenses |
$ |
130 |
|
|
$ |
134 |
|
|
$ |
469 |
|
|
$ |
528 |
|
Adjusted for: |
|
|
|
|
|
|
|
||||||||
Spin-related costs (1) |
|
(6 |
) |
|
|
(2 |
) |
|
|
(11 |
) |
|
|
(12 |
) |
Stock-based compensation |
|
(5 |
) |
|
|
(5 |
) |
|
|
(18 |
) |
|
|
(16 |
) |
Adjusted Non-GAAP Research and development expenses |
$ |
119 |
|
|
$ |
127 |
|
|
$ |
440 |
|
|
$ |
500 |
|
|
|
|
|
|
|
|
|
||||||||
(1) Spin-related costs include costs from the separation of Merck & Co., Inc., |
Organon & Co. |
|||||||||||||||
Reconciliation of GAAP Reported to Non-GAAP Adjusted Metrics (Continued) |
|||||||||||||||
(Unaudited, $ in millions except per share amounts) |
|||||||||||||||
|
|||||||||||||||
|
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
GAAP Reported Net Income |
$ |
109 |
|
|
$ |
546 |
|
|
$ |
864 |
|
|
$ |
1,023 |
|
Adjusted for: |
|
|
|
|
|
|
|
||||||||
Cost of sales adjustments |
|
69 |
|
|
|
49 |
|
|
|
229 |
|
|
|
182 |
|
Selling, general and administrative adjustments |
|
53 |
|
|
|
68 |
|
|
|
189 |
|
|
|
337 |
|
Research and development adjustments |
|
11 |
|
|
|
7 |
|
|
|
29 |
|
|
|
28 |
|
Restructuring |
|
8 |
|
|
|
58 |
|
|
|
31 |
|
|
|
62 |
|
Change in fair value of contingent consideration |
|
11 |
|
|
|
— |
|
|
|
11 |
|
|
|
— |
|
Other expense, net |
|
2 |
|
|
|
4 |
|
|
|
16 |
|
|
|
17 |
|
Tax impact on adjustments above(1) |
|
(28 |
) |
|
|
(506 |
) |
|
|
(304 |
) |
|
|
(588 |
) |
Non-GAAP Adjusted Net Income |
$ |
235 |
|
|
$ |
226 |
|
|
$ |
1,065 |
|
|
$ |
1,061 |
|
|
|
|
|
|
|
|
|
||||||||
(1) For the three months ended December 31, 2024 and 2023, the GAAP income tax rates were |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
GAAP Diluted Earnings per Share |
$ |
0.42 |
|
|
$ |
2.13 |
|
|
$ |
3.33 |
|
|
$ |
3.99 |
|
Total impact of Non-GAAP adjustments |
|
0.48 |
|
|
|
(1.25 |
) |
|
|
0.78 |
|
|
|
0.15 |
|
Non-GAAP Diluted Earnings per Share |
$ |
0.90 |
|
|
$ |
0.88 |
|
|
$ |
4.11 |
|
|
$ |
4.14 |
|
TABLE 5
Organon & Co. |
|||||||||||||||
Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA |
|||||||||||||||
(Unaudited, $ in millions) |
|||||||||||||||
|
Three Months Ended
|
|
Year Ended
|
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Net income |
$ |
109 |
|
|
$ |
546 |
|
|
$ |
864 |
|
|
$ |
1,023 |
|
Depreciation (1) |
|
33 |
|
|
|
30 |
|
|
|
126 |
|
|
|
118 |
|
Amortization |
|
43 |
|
|
|
28 |
|
|
|
145 |
|
|
|
116 |
|
Interest expense |
|
132 |
|
|
|
129 |
|
|
|
520 |
|
|
|
527 |
|
Income tax expense (benefit) |
|
20 |
|
|
|
(442 |
) |
|
|
(57 |
) |
|
|
(350 |
) |
EBITDA (Non-GAAP) |
$ |
337 |
|
|
$ |
291 |
|
|
$ |
1,598 |
|
|
$ |
1,434 |
|
Restructuring costs |
|
8 |
|
|
|
58 |
|
|
|
31 |
|
|
|
62 |
|
Spin-related costs (2) |
|
17 |
|
|
|
70 |
|
|
|
121 |
|
|
|
254 |
|
Manufacturing network related (3) |
|
15 |
|
|
|
— |
|
|
|
54 |
|
|
|
— |
|
Acquisition-related costs (4) |
|
31 |
|
|
|
— |
|
|
|
35 |
|
|
|
— |
|
Change in fair value of contingent consideration |
|
11 |
|
|
|
— |
|
|
|
11 |
|
|
|
— |
|
Other costs (5) |
|
3 |
|
|
|
3 |
|
|
|
3 |
|
|
|
93 |
|
Stock-based compensation |
|
26 |
|
|
|
27 |
|
|
|
105 |
|
|
|
101 |
|
Adjusted EBITDA (Non-GAAP) |
$ |
448 |
|
|
$ |
449 |
|
|
$ |
1,958 |
|
|
$ |
1,944 |
|
Adjusted EBITDA margin (Non-GAAP) |
|
28.1 |
% |
|
|
28.1 |
% |
|
|
30.6 |
% |
|
|
31.0 |
% |
|
|
|
|
|
|
|
|
||||||||
(1) Excludes accelerated depreciation included in one-time costs. |
|||||||||||||||
(2) Spin-related costs reflect certain costs incurred in connection with activities taken to separate Organon from Merck & Co., Inc., |
|||||||||||||||
(3) Manufacturing network related costs, including exiting of temporary manufacturing and supply agreements with Merck & Co., Inc., |
|||||||||||||||
(4) Acquisition-related costs for the three months ended December 31, 2024 reflect |
|||||||||||||||
(5) Other costs for the year ended December 31, 2023, include |
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
As the costs described in (1) through (5) above are directly related to the separation of Organon and acquisition related activities and therefore arise from a one-time event outside of the ordinary course of the company’s operations, the adjustment of these items provides meaningful, supplemental, information that the company believes will enhance an investor's understanding of the company's ongoing operating performance. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213967301/en/
Media Contacts:
Felicia Bisaro
(646) 703-1807
Karissa Peer
(614) 314-8094
Investor Contacts:
Jennifer Halchak
(201) 275-2711
Renee McKnight
(551) 204-6129
Source: Organon & Co.